4.5 Review

Bladder Cancer

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0059

关键词

-

类别

资金

  1. Bristol-Myers Squibb Company
  2. Genentech, Inc.
  3. Agensys, Inc.
  4. sanofi-aventis U.S. LLC
  5. Endo Pharmaceuticals
  6. GlaxoSmithKline plc
  7. Bayer HealthCare
  8. CureTech Ltd.
  9. Eli Lilly and Company
  10. Merck Co., Inc.
  11. Novartis Pharmaceuticals Corporation
  12. Onyx Pharmaceuticals, Inc.
  13. Alton Pharmaceuticals
  14. Argos Therapeutics, Inc.
  15. Biovex, Inc.

向作者/读者索取更多资源

Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non muscle-invasive and muscle-invasive urothelial carcinoma of the bladder. This version of the guidelines provides extensive reorganization and updates on the principles of chemotherapy management. (JNCCN 2013;11:446-475)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据